AstraZeneca/Daiichi Make Their Case For Dato-DXd In Non-Squamous Lung Cancer

Early-Stage PD-L1/Chemo Combo Data Also Reported

 
• By Mandy Jackson
Futuristic medical concept with blue human lungs
AstraZeneca used a proprietary AI-based model to analyze TROP2 expression • Source: Shutterstock

More from Clinical Trials

More from R&D